Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery
Population
Patients with coronary artery disease undergoing coronary artery bypass graft surgery, including those on…
Design
Guideline
Authors
Discussion
Loading...
Member takes
Implication
Enables tailored antiplatelet timing around CABG to balance bleeding and ischemic risks; extends prior consensus with updated evidence synthesis.
Key Points
- Preoperative aspirin continuation halves mortality without increasing major hemorrhage, whereas dual antiplatelet therapy discontinuation timing depends on ischemic versus bleeding risk.
- Discontinuing clopidogrel at least 5 days prior to coronary artery bypass grafting reduces excessive bleeding, with mortality after surgery dropping to 2.3% with prasugrel versus 8.7%.
- Expert consensus review synthesizes observational and trial evidence to balance stent thrombosis against perioperative hemorrhage, calling for multidisciplinary risk stratification.
Structured PICO
P
Population
Patients with coronary artery disease undergoing coronary artery bypass graft (CABG) surgery, including those on antiplatelet therapy for acute coronary syndromes or prior percutaneous coronary intervention.
I
Intervention
Perioperative management of antiplatelet therapy, including aspirin and P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor).
This expert position paper provides consensus recommendations on balancing the risks of perioperative bleeding and atherothrombotic events through the tailored management and timing of antiplatelet therapy withdrawal before CABG.
Limitations
- Due to the paucity of randomized trials, most of the evidence is still derived from observational studies and expert consensus
- Paucity of randomized trials
- Most evidence is derived from observational studies and expert consensus
Cite This Study
Sousa‐Uva et al. (2014) conducted a review in Coronary artery bypass graft surgery (CABG). Antiplatelet therapy was evaluated. This expert position paper reviews the evidence and provides recommendations for the management of antiplatelet therapy before and after coronary artery bypass graft surgery.